Literature DB >> 26032110

The expanding field of IgG4-mediated neurological autoimmune disorders.

M G Huijbers1,2, L A Querol3, E H Niks1, J J Plomp1, S M van der Maarel2, F Graus3, J Dalmau3, I Illa3, J J Verschuuren1.   

Abstract

At least 13 different disease entities affecting the central nervous system, peripheral nervous system and connective tissue of the skin or kidneys are associated with immunoglobulin G4 (IgG4) immune reactivity. IgG4 has always been considered a benign, non-inflammatory subclass of IgG, in contrast to the well-known complement-activating pro-inflammatory IgG1 subclass. A comprehensive review of these IgG4 autoimmune disorders reveals striking similarities in epitope binding and human leukocyte antigen (HLA) associations. Mechanical interference of extracellular ligand-receptor interactions by the associated IgG4 antibodies seems to be the common/converging disease mechanism in these disorders.
© 2015 EAN.

Entities:  

Keywords:  CIDP; IgG4; Iglon5; Lgi1; MuSK myasthenia gravis; autoimmunity; membranous nephropathy; neurofascin; pemphigus

Mesh:

Substances:

Year:  2015        PMID: 26032110     DOI: 10.1111/ene.12758

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  61 in total

Review 1.  Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin.

Authors:  Eva L Feldman; Richard A C Hughes; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2015-10-13       Impact factor: 42.937

Review 2.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 3.  Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.

Authors:  Josep Dalmau; Christian Geis; Francesc Graus
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

4.  Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).

Authors:  M Çebi; H Durmuş; V Yılmaz; S P Yentür; F Aysal; P Oflazer; Y Parman; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2019-04-12       Impact factor: 4.330

5.  Errors in data interpretation from genetic variation of human analytes.

Authors:  Heather L Howie; Meghan Delaney; Xiaohong Wang; Lay See Er; Linda Kapp; Jenna N Lebedev; James C Zimring
Journal:  JCI Insight       Date:  2017-07-06

6.  Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome.

Authors:  Helena Ariño; Thais Armangué; Mar Petit-Pedrol; Lidia Sabater; Eugenia Martinez-Hernandez; Makoto Hara; Eric Lancaster; Albert Saiz; Josep Dalmau; Francesc Graus
Journal:  Neurology       Date:  2016-07-27       Impact factor: 9.910

Review 7.  IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.

Authors:  Maartje G Huijbers; Jaap J Plomp; Silvère M van der Maarel; Jan J Verschuuren
Journal:  Ann N Y Acad Sci       Date:  2018-01-28       Impact factor: 5.691

8.  Association Between Pemphigus and Neurologic Diseases.

Authors:  Khalaf Kridin; Shira Zelber-Sagi; Doron Comaneshter; Arnon D Cohen
Journal:  JAMA Dermatol       Date:  2018-03-01       Impact factor: 10.282

9.  Proteomic Analysis of the Spatio-temporal Based Molecular Kinetics of Acute Spinal Cord Injury Identifies a Time- and Segment-specific Window for Effective Tissue Repair.

Authors:  Stephanie Devaux; Dasa Cizkova; Jusal Quanico; Julien Franck; Serge Nataf; Laurent Pays; Lena Hauberg-Lotte; Peter Maass; Jan H Kobarg; Firas Kobeissy; Céline Mériaux; Maxence Wisztorski; Lucia Slovinska; Juraj Blasko; Viera Cigankova; Isabelle Fournier; Michel Salzet
Journal:  Mol Cell Proteomics       Date:  2016-06-01       Impact factor: 5.911

10.  Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia.

Authors:  Kristina R Patterson; Josep Dalmau; Eric Lancaster
Journal:  Ann Neurol       Date:  2018-01-10       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.